Keep strict vigil to prevent black marketing of COVID drug Remdesivir: Health Ministry to States
The Directorate General of Health Services under the Health Ministry has written to the Drug Controllers of the states to prevent sale of Remdesivir above MRP.
New Delhi: The Union Health Ministry has asked all the states to strengthen their vigil so that black marketing of Covid-19 drug Remdesivir is prevented.
The Directorate General of Health Services under the Health Ministry has written to the Drug Controllers of the states to prevent sale of Remdesivir above MRP.
The Central Drugs Standard Control Organisation has given approval for the manufacturing and marketing of Remdesivir to Cipla, Hetro and Mylan.
The DGHS said that it has received a letter from LocalCircles routed through the Health Ministry, raising concerns over black marketing and overpricing of Remdesivir by certain unscrupulous persons.
"In view of the above, you are requested to instruct your enforcement officials to keep strict vigil on the matter to prevent black marketing and sale of Remdesivir injection above the MRP," the DGHS said in the letter to the states.
Read also: Cipla launches Cipremi at Rs 4,000 per vial
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.